Viking’s VK2809 looks at least as good as Madrigal’s MGL-3196 in liver disease – but investors should be careful of making comparisons.
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.
A partial interim trial success could give GKT831 a new lease of life in liver diseases but full data, due next year, will be watched closely.
Trailing the leaders in amyloidosis and Nash, the respective small caps Eidos and Conatus look to mid-stage trial readouts to demonstrate their relevance.
BAN2401 may work better in genetically defined population, but with safety risks.
Crunch time nears for oral semaglutide and Novo will find out if concizumab can cut it in a crowded haemophilia market.
Genkyotex hopes for a reboot with upcoming data on its previously failed lead project, GKT831, in primary biliary cirrhosis.
The big pharma’s cystic fibrosis deal with Galapagos is greeted with surprise, but the gamble might actually make sense.
The company's stock slumped on disappointing data from its sitravatinib-Opdivo combo lung cancer study, and on news that the group will will need to carry out a…